New Key Statistics Module, Z-Score and F-Score
NAS:BTAI Key Ratios
| Market Cap $ M | 77.40 |
| Enterprise Value $ M | 113.56 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 43.54 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 1.00 |
| EPS (TTM) $ | -6.14 |
| Beneish M-Score | 2.24 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -34.10 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.69 |
| EV-to-EBITDA | -0.69 |
| PEG | -- |
| Shares Outstanding M | 37.03 |
| Net Margin (%) | -12,974.86 |
| Operating Margin % | -12,146.45 |
| Pre-tax Margin (%) | -12,974.86 |
| Quick Ratio | 2.57 |
| Current Ratio | 2.65 |
| ROA % (ttm) | -127.86 |
| ROE % (ttm) | -2,323.67 |
| ROIC % (ttm) | -2,730.34 |
| Dividend Yield % | -- |
| Altman Z-Score | -17.53 |
BTAI Number of Guru Trades
BTAI Volume of Guru Trades
Gurus Latest Trades with NAS:BTAI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:BTAI is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
BioXcel Therapeutics Inc Insider Transactions
No Available Data
News about NAS:BTAI
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers